Verastem FY2025 EPS Forecast Raised by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has raised its FY2025 earnings per share (EPS) forecast for Verastem to ($2.60), an improvement from the previous estimate of ($2.72).
• Verastem's recent earnings report showed an EPS of ($0.39), beating consensus expectations by $0.25.
• The stock has a current consensus rating of Moderate Buy along with a target price of $13.29 based on analysts' estimates.

Verastem, Inc. (NASDAQ:VSTM - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Verastem in a research note issued to investors on Thursday, October 16th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the biopharmaceutical company will earn ($2.60) per share for the year, up from their previous forecast of ($2.72). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Verastem's current full-year earnings is ($3.02) per share. Cantor Fitzgerald also issued estimates for Verastem's FY2026 earnings at ($2.06) EPS.

Verastem (NASDAQ:VSTM - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.25. The business had revenue of $2.14 million during the quarter, compared to analysts' expectations of $6.01 million.

Other equities analysts have also issued research reports about the company. B. Riley raised Verastem to a "strong-buy" rating in a report on Monday, August 25th. BTIG Research restated a "buy" rating and issued a $20.00 price objective on shares of Verastem in a research note on Tuesday, September 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Verastem in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their price objective on shares of Verastem from $12.00 to $13.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Finally, Zacks Research upgraded shares of Verastem to a "hold" rating in a research note on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $13.29.

Verastem Stock Performance

NASDAQ:VSTM opened at $9.22 on Monday. The firm has a market capitalization of $567.40 million, a PE ratio of -2.81 and a beta of 0.89. The business's fifty day moving average price is $9.04 and its 200 day moving average price is $7.05. The company has a debt-to-equity ratio of 2.06, a current ratio of 3.46 and a quick ratio of 3.44. Verastem has a 12 month low of $2.54 and a 12 month high of $11.24.

Institutional Investors Weigh In On Verastem

Hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new position in Verastem in the second quarter valued at about $8,864,000. Octagon Capital Advisors LP purchased a new position in Verastem in the first quarter valued at about $10,372,000. BVF Inc. IL increased its holdings in Verastem by 62.1% in the second quarter. BVF Inc. IL now owns 3,404,425 shares of the biopharmaceutical company's stock valued at $14,128,000 after buying an additional 1,303,957 shares in the last quarter. Foresite Capital Management VI LLC purchased a new position in Verastem in the second quarter valued at about $5,298,000. Finally, Nantahala Capital Management LLC increased its holdings in Verastem by 28.5% in the second quarter. Nantahala Capital Management LLC now owns 2,954,735 shares of the biopharmaceutical company's stock valued at $12,262,000 after buying an additional 656,194 shares in the last quarter. Institutional investors and hedge funds own 88.37% of the company's stock.

Insider Buying and Selling

In related news, Director Paul A. Bunn sold 8,333 shares of the firm's stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $9.06, for a total value of $75,496.98. Following the completion of the sale, the director owned 8,333 shares in the company, valued at $75,496.98. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 11,005 shares of company stock valued at $96,552 in the last three months. 2.10% of the stock is owned by company insiders.

Verastem Company Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.